Newsletter | November 22, 2021

11.22.21 -- Manufacturing Strategies For New Modalities In Gene Therapy

Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness

A rationale-based methodology to address T-cell manufacturing challenges, based on the intended final manufacturing process, proposes a robust, scalable, cost-effective, and sustainable allogeneic platform.

Manufacturing Innovation Across New Modalities

The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, present an opportunity for innovators to make these new modalities available at scale.

Accelerated Growth And Accompanying Challenges In Gene Therapy

There is an abundance of gene therapy-related activity, a clinical pipeline in a high-growth phase, and an influx of venture capital funding for gene therapy companies. Yet, there are challenges: scalability, dosing, and the price of the final treatment.

Integrated Solutions For Advanced Therapeutics

Catalent Cell & Gene Therapy offers best-in-class expertise in bridging the gap from process development to commercial manufacturing. Our strategic partnerships coupled with our integrated solutions across viral vector production, autologous and allogeneic manufacturing, and clinical supply solutions offers customers leading expertise across the cell therapy supply chain.

Request Information